News

GSK enters US$200m PPP
Enlarge image

BusinessUK

GSK enters US$200m PPP

24.05.2013 - GSK has entered into a public-private partnership with the federal US agency BARDA to develop new antibiotics and drugs against potential bioweapons.

The first-ever public-private partnership of the Biomedical Advanced Research and Development Authority (BARDA) with a pharma company could be worth up to US$200m if the collaboration proves effective after 18 months. The two partners will jointly develop anti-infectives to treat infections with bugs that have become a medical threat due to their resistance to common antibiotics. Additionally, the collaboration aims at developing drugs against pathogens that could become a civil threat due to their potential use as a bioweapon. Both topics are priorities of the National Health Security Strategy as well as the BARDA’s 2011-2016 working plan.

The initial funding for the Public-Private Partnership of US$40m for the first 18 months will give GSK the possibility to further develop promising candidates from its antibiotics portfolio with a lowered investment risk for the drugmaker. While return-on-investment in the antibiotics space has become low, most large drug-makers have focused on more lucrative and financially less risky disease areas. David Payne, head of GSK's antibacterial discovery unit, said public-private partnerships, like the one with BARDA, were a key part to solving the problem.

GSK is already involved in the Innovative Medicine’s Initiative’s programme against antibiotic resistance. But while the IMI programme is focused on bringing Phase III drugs to the market and to find strategies against Gram-negative bacteria, the compounds covered by the BARDA deal are still in early safety testing.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/gsk-enters-us200m-ppp.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF21.8%
  • MAGFORCE6.90 EUR10.8%
  • BB BIOTECH140.45 EUR5.1%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.85 EUR-19.5%
  • VITA 343.75 EUR-17.6%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR188.4%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-68.1%
  • MERCK KGAA66.20 EUR-43.4%

No liability assumed, Date: 26.08.2014